Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceDiscovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyTrends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureCharacterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIVHIV-1 antiretroviral resistance: scientific principles and clinical applicationsTrends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in MoroccoDesign and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States.Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014.Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalEpidemiology of Antiretroviral Multiclass Resistance
P2860
Q21092230-52F2E8F6-EDF0-4C99-8359-46B27526FD55Q24534620-F382E570-5039-4D2B-8511-04B4EF8831E4Q24538955-287B1B93-4F30-4350-84AC-5F56F999C657Q28488769-9518D553-E2FE-421B-8A9C-8423BB019EB6Q28533767-2F9EE9DC-752A-4BF0-9C09-BB61402E0044Q33483060-B058BB22-3A23-44D5-97E9-808DA6BE11A9Q33703513-BD19F66A-F0F3-4275-A731-F4F4A5B20E26Q34280466-191EDEA0-0A60-4D8C-8958-0FF0C8043B28Q34468059-6D4A2743-058F-4D8E-91FE-5E241D955E1FQ35034306-9428AC33-53C1-4615-9EA0-EAFCB0DDCDDEQ36015636-CF252511-17C1-4A66-B9DE-FC58EB9D8384Q36102579-20742A63-F79A-4890-8DBD-786D96EDA567Q36425068-B85D676B-F84D-4088-8888-3706CEF79621Q36506829-1030C1C0-E2C4-402E-8065-9A425C655698Q36509584-5CE17D72-B1E3-4095-AAB3-71EBA97B307FQ36580751-9C3CB4DB-C12A-4370-96E3-CACCB79B670EQ37189622-91B62D21-2FA6-4390-8CCF-985F761DC352Q37529910-B9A3B08B-B609-46D9-AAC1-F6B84A1031F9Q40047145-708A962F-297D-452E-9FA9-3483AA734261Q41216109-34157353-2F56-43C5-9912-F6628DB78C76Q42742963-580F04BC-D3DE-4FC9-A9F0-B9EF7BA46127Q57259606-E17F11F5-84A7-4494-B821-8A6A7E3C5AFB
P2860
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@en
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@nl
type
label
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@en
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@nl
prefLabel
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@en
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@nl
P2093
P356
P1476
Estimating HIV-1 drug resistan ...... viduals in the United Kingdom.
@en
P2093
Andrew Phillips
Barry Evans
David Dunn
Hannah Green
Ryanne Matthias
UK Collaborative Group on HIV Drug Resistance
P304
P356
10.1086/432763
P407
P577
2005-08-12T00:00:00Z